Mesalamine
FDA Approved
Description
Mesalamine is an aminosalicylate anti-inflammatory agent that acts locally in the colon and rectum. It is used for the treatment of inflammatory bowel disease and has shown benefit in managing radiation-induced proctitis. The rectal formulation delivers the medication directly to the affected tissue, reducing inflammation and promoting mucosal healing.
Indications & Therapeutic Use
Ulcerative colitis, radiation proctitis, proctosigmoiditis
Linked Diseases:
Radiation proctitis
K62.7
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Mesalamine
| Generic Name | Mesalamine |
| Brands | 1 brand available |
| Active Ingredient | Mesalamine |
| Drug Class | Ulcerative colitis |
| Manufacturer | Allergan |
| Dosage Forms | Rectal suppository 1000mg, rectal suspension 4g/60mL, oral tablet 400mg, 800mg, 1200mg |
| Medical Code | A07EC02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes